Drug Type Monoclonal antibody |
Synonyms ETI 210, ETI-210 |
Target |
Action modulators, stimulants |
Mechanism C3b modulators(complement C3b modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement activation stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Preclinical | United States | 15 Jul 2004 | |
Non-Hodgkin Lymphoma | Preclinical | United States | 15 Jul 2004 | |
Solid tumor | Preclinical | - | - |